Thiarabine hydrochloride
Thiarabine (OSI-7836) hydrochloride is an orally active cytotoxic antitumor agent that acts as a deoxycytidine kinase substrate and a DNA chain terminator. Thiarabine hydrochloride is metabolized to form its major active metabolite T-araCTP, which potently inhibits DNA synthesis and exhibits a long retention time in tumor cells. Thiarabine hydrochloride is widely applicable to research related to leukemia, lymphoma, hematologic malignancies, acute myeloid leukemia, and advanced solid malignancies.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 1060763-87-2
- Formule: C9H14ClN3O4S
- Masse moléculaire:295.74
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
Description
In Vitro
Thiarabine hydrochloride (1-10 μM) potently inhibits the growth of a panel of human tumor cell lines with IC50 values of 1 to 10 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Thiarabine (22.5-90 mg/kg/dose; i.p.; daily; 9 consecutive days, days 1-9) hydrochloride is fully ineffective against thiarabine-resistant P388/T-araC leukemia in CD2F1 mice[1].
Thiarabine (100 mg/kg/dose; i.p.; single dose) hydrochloride is converted to its active metabolite T-araCTP at comparable levels in both thiarabine-sensitive P388/0 and thiarabine-resistant P388/T-araC leukemia cells in CD2F1 mice following a 100 mg/kg i.p. dose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CD2F1 Mice (female, implanted intraperitoneally with 10^6 parental P388/0 leukemia cells)[1]
-
Dosage:45 mg/kg/dose; 90 mg/kg/dose
-
Administration:i.p.; daily; 9 consecutive days (days 1-9)
-
Result:Produced a median increase in lifespan (ILS) of +136% in passage 0 parental P388/0-bearing mice, with a median treated lifespan of 26.0 days versus 11.0 days in untreated controls.
Produced median ILS values ranging from +163% to +220% and net log10 cell kill values ranging from +6.3 to >6.9 units (approximately 1,000,000-fold reduction in tumor burden) across four studies in parental P388/0-bearing mice; 1/6 mice were long-term (60-day) survivors in two of these studies.
-
Animal Model:CD2F1 Mice (female, implanted intraperitoneally with 10^6 thiarabine-resistant P388/T-araC leukemia cells)[1]
-
Dosage:22.5 mg/kg/dose; 45 mg/kg/dose; 90 mg/kg/dose
-
Administration:i.p.; daily; 9 consecutive days (days 1-9)
-
Result:Produced median ILS values ranging from +4% to +13% across passage 8, 21, and selection studies in P388/T-araC-bearing mice, with median treated lifespans only marginally longer than untreated controls.
Produced median ILS values ranging from 0% to +9% and net log10 cell kill values of -1.8 to -1.9 units (almost 100-fold leukemia growth during treatment) across four studies in P388/T-araC-bearing mice; no long-term (60-day) survivors were observed.
Produced a median ILS of +8% in passage 8 P388/T-araC-bearing mice.
Chemical Information
-
CAS No. 1060763-87-2
-
Masse moléculaire 295.74
-
Formule C9H14ClN3O4S
-
SMILES
O[C@@H]1[C@H](N2C(N=C(C=C2)N)=O)S[C@@H]([C@H]1O)CO.Cl
-
Synonyms
OSI-7836 hydrochloride
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocole
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Pureté et documentation
Références
[1]. Waud WR, et al.. Isolation and characterization of a murine P388 leukemia line resistant to thiarabine. Nucleosides, nucleotides & nucleic acids. 2012;31(1):14-27. [Content Brief]
[2]. Parker WB, et al.. Thiarabine, 1-(4-Thio-β-D-arabinofuranosyl)cytosine. A Deoxycytidine Analog With Excellent Anticancer Activity. Current medicinal chemistry. 2015;22(34):3881-96. [Content Brief]
[3]. Jordheim LP, et al.. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nature reviews. Drug discovery. 2013 Jun;12(6):447-64. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)